Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-10-17
1992-06-09
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 424 858, 436 63, A61K 39395, A61K 3704, A61K 4900
Patent
active
051207141
ABSTRACT:
A method for the diagnosis of human granulomatous inflammatory disease comprising determining the level of Granuloma Enhancing Factor (GEF) activity in a bodily fluid and comparing said level to established diagnostic levels is provided. Methods for treatment of human granulomatous diseases are also provided.
REFERENCES:
Patrick et al., Am Rev Respir Dis 141 (4 part 2) 1990 A796.
Patrick et al., Am Rev. Respir. Dis 139 (4 part 2) 1989, A455.
Turk, J. L. et al., "The mononuclear phagocyte system in granulomas", Brit. J. Derm. 1985; 113:49-54.
Takizawa et al., "Granulomatous pneumonitis induced by Bacille Calmette-Guerin in the mouse and its treatment with cyclosporin", 1986; 134:296-299.
Chang et al., "Histology of granulomatous inflammation in nude rats lungs induced by complete Freund's Adjuvant (CFA)",
Grassi et al.: Sarcoidosis and other Granulomatous Disorders, Amsterdam: Excerpta Medica; 1988, pp. 717-718).
Carrick and Boros, "The artificial granuloma 1: in vitro lumphokine production by pulmonary artificial hypersensitivity granulomas", Clin Immun and Immunopath, 1980: 17:415-426.
Horowitz et al., "Angiotensin converting enzyme concentrations in rabbit with talc-induced pulmonary granulomatosis", Am Rev Resp Dis, 1981; 124:306-309.
Remick et al., "Flow-cytometric evaluation of lymphocyte subpopulations in synchronously developing Schistosoma mansoni egg and sephadex bed pulmonary granulomas", Am J Path, 1988; 131:298-307.
Newman, "Antigen-specific T-cells in a mouse model of beryllium disease", Grassi C., Rizzato G. Pozzi E., eds.: Sarcoidosis and Other Granulomatous Disorders, Amsterdam: Excerpta Medica; 1988, pp. 715-716.
Kasahara et al., "Direct evidence for granuloma-inducing activity of interleukin-1: induction of experiental pulmonary granuloma formation in mice by interleukin-1-coupled beads", Am J Path, 1988, 130:629-637.
Boros, D. l., "Immunoregulation of granuloma formation in murine Schistosomiasis mansoni", Ann NY Acad Sci, 1986; 465:313-323.
deBrito et al., "Host granulomatous response in Schistosoma mansoni-antibody and cell-mediated damage of parasite eggs in vitro", J Clin Invest, 1984; 74:1715-1723.
Doughty et al., "Delayed type hypersensitivity granuloma formation around Schistosoma mansoni eggs in vitro", Am J Trop Med Hyg 1984; 33:1173-1177.
Ohta et al., "Schistosoma japonicum egg antigen-specific T-cell lines in man-induction of helper and suppressor T-cell lines and clones in vitro in a patient with chronic Schistosoma japonica", J Clin Invest, 1988; 775-781.
Bentley et al., "In vitro delayed hypersensitivity granuloma formation-development of an antigen-coated bead model", J Immunol, 1985; 134:4163-4169.
Mishra et al. "In-vitro sarcoid granulomas--differences between active and inactive disease", Grassi et al.: Sarcoidosis and Other Granulomatous Disorders, Amsterdam: Excerpta Medica; 1988, pp. 151-154.
Maguire, G. A., et al., "A continuous monitoring spectrophotometric method for the measurement of angiotensin converting enzyme in human serum", Ann Clin Biochem, 1985; 22:204-210.
Koh Choon
Schain Howard E.
Thomas Jefferson University
LandOfFree
Method for the diagnosis and treatment of human granulomatous in does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the diagnosis and treatment of human granulomatous in, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the diagnosis and treatment of human granulomatous in will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1804499